On September 2, 2021 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, reported that company management will participate in the following upcoming virtual investor conferences (Press release, AC Immune, SEP 2, 2021, View Source [SID1234587188]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Citi’s 16th Annual BioPharma Virtual Conference
One-on-one meetings – Wednesday, September 8, 2021
Morgan Stanley’s 19th Annual Global Healthcare Conference
One-on-one meetings – Friday, September 10, 2021
H.C. Wainwright 23rd Annual Global Investment Conference
Corporate presentation – On-demand starting on September 13, 2021
One-on-one meetings – Wednesday, September 15, 2021
During the conferences, Prof. Andrea Pfeifer, CEO, AC Immune SA, will discuss the Company’s corporate strategy and precision medicine approach, while highlighting its clinical-stage vaccine programs targeting phospho-Tau, Abeta, and alpha-synuclein in neurodegenerative diseases as well as the recent top-line data from Lauriet Phase 2 trial evaluating semorinemab in mild-to-moderate AD.
A webcast of the corporate presentation will be available on the Events Page of AC Immune’s website.